Mo  Qatanani net worth and biography

Mo Qatanani Biography and Net Worth

Insider of Scholar Rock

Mo Qatanani joined Scholar Rock in 2021 and has served as Chief Scientific Officer since 2024. He is responsible for all research functions, including discovery biology, protein sciences & antibody engineering, safety and translational sciences. Mo brings more than 15 years of discovery and translational research experience in developing and advancing multiple therapeutic modalities across many disease areas in the biotech and pharmaceutical industry. Prior to Scholar Rock, Mo was a founding employee, vice president, and Head of Research at Dyne Therapeutics, where he built the research organization from the ground up to launch and advance to the clinic multiple therapeutic programs for rare neuromuscular diseases. Prior to Dyne, Mo held research positions of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, and Merck. Mo holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.

What is Mo Qatanani's net worth?

The estimated net worth of Mo Qatanani is at least $4.92 million as of September 22nd, 2025. Dr. Qatanani owns 108,964 shares of Scholar Rock stock worth more than $4,917,436 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Qatanani may own. Learn More about Mo Qatanani's net worth.

How old is Mo Qatanani?

Dr. Qatanani is currently 51 years old. There are 6 older executives and no younger executives at Scholar Rock. The oldest executive at Scholar Rock is Dr. Jay Thomas Backstrom M.D., M.P.H., President, CEO & Director, who is 69 years old. Learn More on Mo Qatanani's age.

How do I contact Mo Qatanani?

The corporate mailing address for Dr. Qatanani and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Mo Qatanani's contact information.

Has Mo Qatanani been buying or selling shares of Scholar Rock?

Mo Qatanani has not been actively trading shares of Scholar Rock over the course of the past ninety days. Most recently, Mo Qatanani sold 3,353 shares of the business's stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $30.67, for a transaction totalling $102,836.51. Following the completion of the sale, the insider now directly owns 108,964 shares of the company's stock, valued at $3,341,925.88. Learn More on Mo Qatanani's trading history.

Who are Scholar Rock's active insiders?

Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.

Are insiders buying or selling shares of Scholar Rock?

In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.

Information on this page was last updated on 10/6/2025.

Mo Qatanani Insider Trading History at Scholar Rock

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/22/2025Sell3,353$30.67$102,836.51108,964View SEC Filing Icon  
9/16/2025Sell3,178$33.52$106,526.56112,317View SEC Filing Icon  
7/8/2025Sell24,066$34.44$828,833.04115,495View SEC Filing Icon  
2/19/2025Sell68,510$37.40$2,562,274.00111,084View SEC Filing Icon  
9/16/2024Sell1,936$8.58$16,610.88142,768View SEC Filing Icon  
6/17/2024Sell2,315$8.98$20,788.70144,704View SEC Filing Icon  
2/16/2024Sell2,512$15.74$39,538.88147,019View SEC Filing Icon  
1/16/2024Sell2,002$15.93$31,891.8678,816View SEC Filing Icon  
9/18/2023Sell1,945$6.34$12,331.3097,043View SEC Filing Icon  
See Full Table

Mo Qatanani Buying and Selling Activity at Scholar Rock

This chart shows Mo Qatanani's buying and selling at Scholar Rock by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scholar Rock Company Overview

Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $45.20
Low: $42.83
High: $45.50

50 Day Range

MA: $34.97
Low: $27.92
High: $45.20

2 Week Range

Now: $45.20
Low: $22.71
High: $46.98

Volume

1,340,235 shs

Average Volume

2,069,553 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61